List of Tolero Pharmaceuticals patents

List of Tolero Pharmaceuticals patents

List of Yubico patents

List of Recombinetics patents

List of Solae (company) patents

List of AI water industry companies

List of companies in Aiyun Ventures's investment portfolio

Patents where

Current Assignee

Name

is

Tolero Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10267787 Profiling peptides and methods for sensitivity profiling	Patent 10267787 was granted and assigned to Tolero Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10267787	April 23, 2019
	‌ US Patent 10422788 Profiling peptides and methods for sensitivity profiling	Patent 10422788 was granted and assigned to Tolero Pharmaceuticals on September, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10422788	September 24, 2019
	‌ US Patent 10132797 Profiling peptides and methods for sensitivity profiling	Patent 10132797 was granted and assigned to Tolero Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10132797	November 20, 2018
	‌ US Patent 10568887 Combination therapies for treatment of cancer	Patent 10568887 was granted and assigned to Tolero Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10568887	February 25, 2020
	‌ US Patent 10357488 Predicting response to alvocidib by mitochondrial profiling	Patent 10357488 was granted and assigned to Tolero Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10357488	July 23, 2019
	‌ US Patent 10207996 PKM2 modulators and methods for their use	Patent 10207996 was granted and assigned to Tolero Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10207996	February 19, 2019
	‌ US Patent 10259835 Alvocidib prodrugs having increased bioavailability	Patent 10259835 was granted and assigned to Tolero Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10259835	April 16, 2019
	‌ US Patent 10562925 Alvocidib prodrugs having increased bioavailability	Patent 10562925 was granted and assigned to Tolero Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10562925	February 18, 2020
	‌ US Patent 9394257 PKM2 modulators and methods for their use	Patent 9394257 was granted and assigned to Tolero Pharmaceuticals on July, 2016 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	9394257	July 19, 2016
	‌ US Patent 10472328 PKM2 modulators and methods for their use	Patent 10472328 was granted and assigned to Tolero Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10472328	November 12, 2019
	‌ US Patent 10202356 JAK2 and ALK2 inhibitors and methods for their use	Patent 10202356 was granted and assigned to Tolero Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10202356	February 12, 2019
	‌ US Patent 10682356 Combination therapies for treatment of cancer	Patent 10682356 was granted and assigned to Tolero Pharmaceuticals on June, 2020 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10682356	June 16, 2020
	‌ US Patent 9901574 Predicting response to alvocidib by mitochondrial profiling	Patent 9901574 was granted and assigned to Tolero Pharmaceuticals on February, 2018 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	9901574	February 27, 2018
	‌ US Patent 10624880 Predicting response to alvocidib by mitochondrial profiling	Patent 10624880 was granted and assigned to Tolero Pharmaceuticals on April, 2020 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10624880	April 21, 2020
	‌ US Patent 9758539 Alvocidib prodrugs having increased bioavailability	Patent 9758539 was granted and assigned to Tolero Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	9758539	September 12, 2017
	‌ US Patent 8710057 Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors	Patent 8710057 was granted and assigned to Tolero Pharmaceuticals on April, 2014 by the United States Patent and Trademark Office.		Tolero Pharmaceuticals		United States Patent and Trademark Office	8710057	April 29, 2014
	‌ US Patent 10392392 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors	Patent 10392392 was granted and assigned to Tolero Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10392392	August 27, 2019
	‌ US Patent 10047093 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors	Patent 10047093 was granted and assigned to Tolero Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.	Tolero Pharmaceuticals	Tolero Pharmaceuticals		United States Patent and Trademark Office	10047093	August 14, 2018
	‌ US Patent 9416132 Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors	Patent 9416132 was granted and assigned to Tolero Pharmaceuticals on August, 2016 by the United States Patent and Trademark Office.		Tolero Pharmaceuticals		United States Patent and Trademark Office	9416132	August 16, 2016

19 results

0 selected

19 results

0 selected